Arcus Biosciences [RCUS] vs Vertex [VRTX] Detailed Stock Comparison
Arcus Biosciences
NYSE
Loading...
Vertex
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Arcus Biosciences wins in 6 metrics, Vertex wins in 11 metrics, with 0 ties. Vertex appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Arcus Biosciences | Vertex | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -3.67 | 28.08 | Arcus Biosciences |
| Price-to-Book Ratio | 2.23 | 5.89 | Arcus Biosciences |
| Debt-to-Equity Ratio | 23.68 | 8.89 | Vertex |
| PEG Ratio | 0.04 | -0.22 | Vertex |
| EV/EBITDA | -1.36 | 20.06 | Arcus Biosciences |
| Profit Margin (TTM) | -113.74% | 31.86% | Vertex |
| Operating Margin (TTM) | -5.00% | 38.93% | Vertex |
| EBITDA Margin (TTM) | N/A | 38.93% | N/A |
| Return on Equity | -50.34% | 22.77% | Vertex |
| Return on Assets (TTM) | -18.69% | 13.09% | Vertex |
| Free Cash Flow (TTM) | $-176.00M | $-978.00M | Arcus Biosciences |
| 1-Year Return | -35.82% | -18.72% | Vertex |
| Price-to-Sales Ratio (TTM) | 4.68 | 8.86 | Arcus Biosciences |
| Enterprise Value | $445.08M | $96.30B | Vertex |
| EV/Revenue Ratio | 1.70 | 8.43 | Arcus Biosciences |
| Gross Profit Margin (TTM) | N/A | 86.25% | N/A |
| Revenue per Share (TTM) | $3 | $44 | Vertex |
| Earnings per Share (Diluted) | $-3.14 | $14.05 | Vertex |
| Beta (Stock Volatility) | 0.83 | 0.44 | Vertex |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Arcus Biosciences vs Vertex Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Arcus Biosciences | 0.17% | -5.50% | 19.13% | 23.21% | 18.76% | -23.86% |
| Vertex | -0.71% | -0.40% | 1.74% | -14.24% | -20.36% | -2.77% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Arcus Biosciences | -35.82% | -55.56% | -47.49% | -34.55% | -34.55% | -34.55% |
| Vertex | -18.72% | 36.18% | 48.66% | 217.76% | 988.36% | 1,933.66% |
News Based Sentiment: Arcus Biosciences vs Vertex
Arcus Biosciences
News based Sentiment: POSITIVE
Arcus Biosciences delivered exceptional Q2 results, exceeding expectations significantly, and continues to advance its clinical programs with promising data. While insider selling and trading volatility exist, the overall narrative is positive, supported by analyst confidence and upcoming catalysts.
Vertex
News based Sentiment: POSITIVE
September was a strong month for Vertex, marked by positive Q2 earnings, successful product launches, and continued pipeline development. While some analyst ratings are mixed, the overall narrative points to continued growth and diversification, making it a compelling investment story.
Performance & Financial Health Analysis: Arcus Biosciences vs Vertex
| Metric | RCUS | VRTX |
|---|---|---|
| Market Information | ||
| Market Cap | $1.23B | $101.15B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 863,370 | 1,277,750 |
| 90 Day Avg. Volume | 794,177 | 2,149,460 |
| Last Close | $11.52 | $394.53 |
| 52 Week Range | $6.50 - $18.98 | $362.50 - $519.88 |
| % from 52W High | -39.30% | -24.11% |
| All-Time High | $49.10 (Nov 22, 2021) | $519.88 (Nov 04, 2024) |
| % from All-Time High | -76.54% | -24.11% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 3.10% | 0.12% |
| Quarterly Earnings Growth | 3.10% | 0.12% |
| Financial Health | ||
| Profit Margin (TTM) | -1.14% | 0.32% |
| Operating Margin (TTM) | -0.05% | 0.39% |
| Return on Equity (TTM) | -0.50% | 0.23% |
| Debt to Equity (MRQ) | 23.68 | 8.89 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $5.16 | $67.02 |
| Cash per Share (MRQ) | $8.56 | $24.90 |
| Operating Cash Flow (TTM) | $-339,000,000 | $3.85B |
| Levered Free Cash Flow (TTM) | $-113,000,000 | $2.91B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Arcus Biosciences vs Vertex
| Metric | RCUS | VRTX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -3.67 | 28.08 |
| Forward P/E | -2.47 | 21.02 |
| PEG Ratio | 0.04 | -0.22 |
| Price to Sales (TTM) | 4.68 | 8.86 |
| Price to Book (MRQ) | 2.23 | 5.89 |
| Market Capitalization | ||
| Market Capitalization | $1.23B | $101.15B |
| Enterprise Value | $445.08M | $96.30B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.70 | 8.43 |
| Enterprise to EBITDA | -1.36 | 20.06 |
| Risk & Other Metrics | ||
| Beta | 0.83 | 0.44 |
| Book Value per Share (MRQ) | $5.16 | $67.02 |
Financial Statements Comparison: Arcus Biosciences vs Vertex
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | RCUS | VRTX |
|---|---|---|
| Revenue/Sales | $28.00M | $2.96B |
| Cost of Goods Sold | N/A | $407.50M |
| Gross Profit | N/A | $2.56B |
| Research & Development | $122.00M | $978.40M |
| Operating Income (EBIT) | $-122.00M | $1.15B |
| EBITDA | $-108.00M | $1.34B |
| Pre-Tax Income | $-112.00M | $1.28B |
| Income Tax | $0 | $250.10M |
| Net Income (Profit) | $-112.00M | $1.03B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | RCUS | VRTX |
|---|---|---|
| Cash & Equivalents | $192.00M | $4.67B |
| Total Current Assets | $1.03B | $10.01B |
| Total Current Liabilities | $192.00M | $3.78B |
| Long-Term Debt | $48.00M | $1.65B |
| Total Shareholders Equity | $531.00M | $16.50B |
| Retained Earnings | $-1.24B | $10.25B |
| Property, Plant & Equipment | N/A | $2.63B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | RCUS | VRTX |
|---|---|---|
| Operating Cash Flow | $-128.00M | $404.90M |
| Capital Expenditures | $-1.00M | $-40.70M |
| Free Cash Flow | $-133.00M | $778.20M |
| Debt Repayment | N/A | $-1.30M |
| Common Stock Repurchase | N/A | $-696.60M |
Short Interest & Institutional Ownership Analysis
| Metric | RCUS | VRTX |
|---|---|---|
| Shares Short | 9.83M | 3.64M |
| Short Ratio | 13.27 | 1.54 |
| Short % of Float | 0.14% | 0.02% |
| Average Daily Volume (10 Day) | 863,370 | 1,277,750 |
| Average Daily Volume (90 Day) | 794,177 | 2,149,460 |
| Shares Outstanding | 92.20M | 256.94M |
| Float Shares | 59.89M | 255.58M |
| % Held by Insiders | 0.35% | 0.00% |
| % Held by Institutions | 0.68% | 0.98% |
Dividend Analysis & Yield Comparison: Arcus Biosciences vs Vertex
| Metric | RCUS | VRTX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |